Georgia's Online Cancer Information Center

Non-Hodgkin Lymphoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Non-Hodgkin Lymphoma
Cancer Type = Non-Hodgkin Lymphoma
There are currently 48 active Non-Hodgkin Lymphoma clinical trials in Georgia.
1.
NCORP Trial
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT00078598
Protocol IDs
CCBX001-049
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
2.
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05972720
Protocol IDs
CRG-022-101
NCI-2023-06284
Treatment Sites (1)
6.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
17-BI1206-02
NCI-2018-02697
Treatment Sites (1)
7.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
8.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT05487170
Protocol IDs
RNK05047-01
NCI-2022-09252
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05451810
Protocol IDs
M23-362
NCI-2022-09111
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
NCORP Trial
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04970901
Protocol IDs
ADCT-402-105
NCI-2022-04828
2021-001071-16
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT06091254
Protocol IDs
R1979-HM-2298
NCI-2024-00238
2022-502660-20-00
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
13.
NCORP Trial
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04673617
Protocol IDs
AB-101-01
NCI-2021-00532
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
14.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
15.
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05653271
Protocol IDs
ACE1831-001
NCI-2023-03335
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05011058
Protocol IDs
VT3996-202
NCI-2021-09770
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT03114865
Protocol IDs
J1713
NCI-2019-00402
CRMS-65830
IRB00125679
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
18.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor
NCT ID
NCT01120353
Protocol IDs
CCSS
U24CA055727
Treatment Sites (2)
19.
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT04637763
Protocol IDs
CB10A
NCI-2021-04061
Treatment Sites (1)
20.
DALY II USA/ MB-CART2019.1 for DLBCL
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04792489
Protocol IDs
M-2018-344
NCI-2021-08357
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04652960
Protocol IDs
10347
10347
NCI-2020-11641
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
23.
NCORP Trial
EHR Tool in Assessing Heart Health among Cancer Survivors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Prostate Cancer , Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT03935282
Protocol IDs
WF-1804CD
WF-1804CD
WF-1804CD
NCI-2019-01362
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
24.
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
NCT ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
APEC1621F
NCI-2017-01243
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
25.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT03501576
Protocol IDs
Winship4236-17
NCI-2017-02313
IRB00101067
Treatment Sites (2)
26.
Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT04996706
Protocol IDs
21-001804
NCI-2022-02481
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
28.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
29.
Long-term Follow-up Study of Allogeneic Gamma Delta (?d) CAR T Cells
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT04911478
Protocol IDs
ADI-20200102
NCI-2021-08684
Treatment Sites (1)
30.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
31.
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05664217
Protocol IDs
18-255-01
NCI-2023-02609
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
32.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03267433
Protocol IDs
EA4151
EA4151
NCI-2016-01403
EA4151
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT05878184
Protocol IDs
SC291-101
NCI-2023-04424
Treatment Sites (1)
34.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05409066
Protocol IDs
M20-638
NCI-2022-09448
2021-000169-34
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT04756726
Protocol IDs
CFT7455-1101
NCI-2021-05587
36.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
37.
Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT05602194
Protocol IDs
ACCL1931
ACCL1931
COG-ACCL1931
NCI-2022-08058
38.
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05910801
Protocol IDs
ACCRU-LY-2101
NCI-2023-03968
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
39.
NCORP Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (3)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
40.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
Treatment Sites (1)
41.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCT ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
42.
Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05976763
Protocol IDs
A052101
A052101
NCI-2023-03577
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
43.
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05633615
Protocol IDs
S2114
S2114
NCI-2022-07930
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
44.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
45.
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04803201
Protocol IDs
A051902
A051902
NCI-2021-01380
Treatment Sites (2)
46.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02495415
Protocol IDs
FEN T-14
NCI-2015-01195
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
47.
Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT03842696
Protocol IDs
UMCC 2018.081
NCI-2019-04695
HUM00147796
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
48.
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT05678998
Protocol IDs
WTX-330x2101
NCI-2023-00670
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180